CompareMarketResearchRequest a sample
Home / Healthcare / Virus Inactivation

Healthcare · Market report

Virus Inactivation Market Size, Share and Forecast 2026-2036

The global virus inactivation market is worth USD 935 mn in 2026 and is forecast to reach USD 2.4 bn by 2036, growing at a 10.0% CAGR. United States is the largest country market and Low pH hold is the largest by method segment.

USD 935 mnMarket size 2026
USD 2.4 bnForecast 2036
10.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global virus inactivation market is worth USD 935 mn in 2026 and is forecast to reach USD 2.4 bn by 2036, growing at a 10.0% CAGR. United States is the largest country market and Low pH hold is the largest by method segment.

ScopeViral inactivation products and services used in biologics manufacturing, including low pH, solvent-detergent, heat and UV-C treatment systems, reagents and viral clearance studies.
IndustryHealthcare
Value 2025USD 850 mn
Value 2026USD 935 mn
Value 2036USD 2.4 bn
CAGR 2026-203610.0%
Volume 2026153 thousand units
Volume 2036378 thousand units
Average price 2026USD 6,102 per unit
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Virus Inactivation market size and forecast, 2026-2036

Exhibit 1The global virus inactivation market is forecast to grow from USD 935 mn in 2026 to USD 2.4 bn by 2036, more than doublingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 10.0%
Virus Inactivation market value, 2025 to 2036Market value by year. 2025: USD 850 mn; 2026: USD 935 mn; 2027: USD 1.0 bn; 2028: USD 1.1 bn; 2029: USD 1.2 bn; 2030: USD 1.4 bn; 2031: USD 1.5 bn; 2032: USD 1.7 bn; 2033: USD 1.8 bn; 2034: USD 2.0 bn; 2035: USD 2.2 bn; 2036: USD 2.4 bn. Compound annual growth rate 2026 to 2036: 10.0%.2025935 mn20261.5 bn20312.4 bn203610.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 935 mn
2027USD 1.0 bn
2028USD 1.1 bn
2029USD 1.2 bn
2030USD 1.4 bn
2031USD 1.5 bn
2032USD 1.7 bn
2033USD 1.8 bn
2034USD 2.0 bn
2035USD 2.2 bn
2036USD 2.4 bn

Virus Inactivation market segmentation

By method

Exhibit 2Low pH hold is the largest segment by method, with 30.0% of 2026 revenueEstimated share of 2026 global revenue, by method
Virus Inactivation market share by method, 2026Share of 2026 revenue by method. Low pH hold: 30.0%; Viral clearance studies: 26.0%; Solvent and detergent: 24.0%; UV-C and other physical: 20.0%.Low pH hold30.0%Viral clearance studies26.0%Solvent and detergent24.0%UV-C and other physical20.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Low pH hold30.0%26.9%USD 280 mn8.8%
Solvent and detergent24.0%20.6%USD 224 mn8.3%
UV-C and other physical20.0%25.7%USD 187 mn12.8%
Viral clearance studies26.0%26.8%USD 243 mn10.3%

By product

Exhibit 3Services adds the most revenue by product, growing from USD 355 mn in 2026 to USD 1.0 bn by 2036Estimated revenue in USD by product, 2026 and 2036 forecast
Virus Inactivation market by product, 2026 and 2036Revenue by product in 2026 and 2036. Services: USD 355 mn in 2026, USD 1.0 bn in 2036, change +183%; Kits and reagents: USD 355 mn in 2026, USD 839 mn in 2036, change +136%; Systems and equipment: USD 224 mn in 2026, USD 580 mn in 2036, change +159%.20262036 forecastChangeServices+183%355 mn1.0 bnKits and reagents+136%355 mn839 mnSystems and equipment+159%224 mn580 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Kits and reagents38.0%34.6%USD 355 mn9.0%
Systems and equipment24.0%23.9%USD 224 mn10.0%
Services38.0%41.5%USD 355 mn11.0%

By end user

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Biopharma62.0%59.2%USD 580 mn9.5%
Contract organisations24.0%27.5%USD 224 mn11.5%
Plasma and blood product makers14.0%13.4%USD 131 mn9.5%

By stage

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Upstream24.0%22.0%USD 224 mn9.1%
Downstream52.0%52.0%USD 486 mn10.0%
Fill-finish24.0%26.0%USD 224 mn10.9%

By biologic

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Monoclonal antibodies52.0%48.0%USD 486 mn9.1%
Plasma derivatives24.0%22.0%USD 224 mn9.1%
Vaccines14.0%16.0%USD 131 mn11.5%
Gene therapy vectors10.0%14.0%USD 94 mn13.8%

Top 25 countries for virus inactivation by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 87.5% of 2026 revenue and the 25 countries below together hold 96.2%.

Exhibit 4United States is the largest country market at USD 355 mn in 2026, and the three largest countries hold 56.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Virus Inactivation market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 355 mn, 38.0%; Germany: USD 94 mn, 10.0%; China: USD 75 mn, 8.0%; Switzerland: USD 56 mn, 6.0%; Japan: USD 47 mn, 5.0%; United Kingdom: USD 47 mn, 5.0%; South Korea: USD 47 mn, 5.0%; France: USD 37 mn, 4.0%; Ireland: USD 33 mn, 3.5%; India: USD 28 mn, 3.0%.United States355 mn 38.0%Germany94 mn 10.0%China75 mn 8.0%Switzerland56 mn 6.0%Japan47 mn 5.0%United Kingdom47 mn 5.0%South Korea47 mn 5.0%France37 mn 4.0%Ireland33 mn 3.5%India28 mn 3.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 355 mn38.0%USD 875 mn9.4%
2GermanyUSD 94 mn10.0%USD 221 mn9.0%
3ChinaUSD 75 mn8.0%USD 264 mn13.5%
4SwitzerlandUSD 56 mn6.0%USD 138 mn9.4%
5JapanUSD 47 mn5.0%USD 99 mn7.8%
6United KingdomUSD 47 mn5.0%USD 114 mn9.3%
7South KoreaUSD 47 mn5.0%USD 143 mn11.8%
8FranceUSD 37 mn4.0%USD 87 mn8.8%
9IrelandUSD 33 mn3.5%USD 80 mn9.3%
10IndiaUSD 28 mn3.0%USD 99 mn13.5%
11NetherlandsUSD 18 mn1.9%USD 45 mn9.4%
12SpainUSD 11 mn1.2%USD 27 mn9.4%
13CanadaUSD 8.0 mn0.8%USD 20 mn9.5%
14ItalyUSD 6.5 mn0.7%USD 16 mn9.3%
15BelgiumUSD 5.4 mn0.6%USD 13 mn9.4%
16DenmarkUSD 4.8 mn0.5%USD 12 mn9.3%
17SwedenUSD 4.2 mn0.5%USD 10 mn9.5%
18AustraliaUSD 3.8 mn0.4%USD 9.5 mn9.4%
19SingaporeUSD 3.5 mn0.4%USD 12 mn13.6%
20TaiwanUSD 3.3 mn0.3%USD 8.0 mn9.3%
21IsraelUSD 3.0 mn0.3%USD 11 mn13.6%
22AustriaUSD 2.8 mn0.3%USD 7.0 mn9.6%
23BrazilUSD 2.6 mn0.3%USD 9.2 mn13.4%
24MexicoUSD 2.5 mn0.3%USD 8.7 mn13.2%
25TurkeyUSD 2.4 mn0.3%USD 8.5 mn13.3%
Rest of worldUSD 35 mn3.8%USD 87 mn9.5%
Exhibit 5United States and China account for 48% of the USD 1.5 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Virus Inactivation market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 935 mn. United States: +USD 520 mn; China: +USD 190 mn; Germany: +USD 127 mn; South Korea: +USD 96 mn; Switzerland: +USD 82 mn; 20 other countries: +USD 423 mn; Rest of world: +USD 52 mn. Market value 2036: USD 2.4 bn.Market value 2026935 mnUnited States+520 mnChina+190 mnGermany+127 mnSouth Korea+96 mnSwitzerland+82 mn20 other countries+423 mnRest of world+52 mnMarket value 20362.4 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Merck KGaA
  • Sartorius
  • Cytiva
  • Charles River Laboratories
  • Pall Corporation

Group 2: Regional and specialist players

  • Asahi Kasei Bioprocess
  • Eurofins
  • WuXi Biologics
  • ViruSure
  • Texcell
  • SGS
  • KBI Biopharma
  • Lonza
  • Cerus
  • Macopharma

Group 3: Emerging and niche players

  • Cobetter Filtration
  • Vironova BioAnalytical

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the virus inactivation market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 10.0% is calculated from the resulting values.

The market is divided by method, by product, by end user, by stage, by biologic. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the virus inactivation market?

The global virus inactivation market is estimated at USD 850 mn in 2025 and USD 935 mn in 2026.

How fast will the virus inactivation market grow?

It is forecast to reach USD 2.4 bn by 2036, a compound annual growth rate of 10.0% from 2026, an increase of USD 1.5 bn.

Which country is the largest market for virus inactivation?

United States is the largest market by revenue at USD 355 mn in 2026, 38.0% of the global total. The three largest countries together hold 56.0%.

Which country is growing fastest?

Among the ten largest markets, India is growing fastest at 13.5% a year from 2026 to 2036.

Which virus inactivation segment is largest?

In the by method split, Low pH hold is the largest segment with 30.0% of 2026 revenue.

Who are the leading virus inactivation companies?

Global leaders include Merck KGaA, Sartorius, Cytiva, Charles River Laboratories.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Vibriosis Treatment Products Waterless Bathing Solution →

All Healthcare markets →

Request a sample